MedPath

Hybrid Versus Cemented TKA Using the NexGen LPS Prosthesis

Not Applicable
Active, not recruiting
Conditions
Total Knee Arthroplasty
Registration Number
NCT02798432
Lead Sponsor
Jesus Moreta Suarez
Brief Summary

Early total knee arthroplasty (TKA) implant systems most frequently used an all-polyethylene cemented tibial component1. Based on finite-element analysis studies reporting superior force distribution compared with conventional all-polyethylene components, metal-backed tibial baseplates have dominated the TKA implant market since the middle of the 1980's2. These modular implants provided excellent long-term implant survivorship3.

As TKA became increasingly successful, younger patients increasingly became eligible. Increasing life expectancy has raised the concern that cemented TKAs may not withstand prolonged use, particularly in younger patients4. Patients younger than 65 years are projected to account for more than 50% of patients undergoing TKA by 2016 and to more than 50% of patients undergoing revision surgery by 2011. The number of total knee revisions in the United States is expected to increase from 38,300 in 2005 to 268,200 in 20305.

Many authors have reported excellent and equivalent results of cemented and cementless TKA6-8. Despite these encouraging reports, the major concern with cementless TKA has been the tibial component, and, therefore, the preference for many surgeons still remains to cement the tibial component9,10. The femoral component may be the most suitable for cementless fixation11-13. However, the best femoral method of fixation is still being discussed. Currently, the decision to cement or not to cement the femoral component is based on the surgeon's preference14.

The current study was designed to compare the hybrid NexGen LPS (Zimmer Inc, Warsaw, IN) and the cemented NexGen LPS. The purpose of this study is to establish whether the hybrid NexGen LPS leads to equally successful results as the cemented TKA gold standard

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria

Patients may be included in the study only if they meet the following criteria:

  • Patient is able to provide informed consent.
  • Patient is between 18 and 75 years of age.
  • Patients are willing and able to attend all follow-up visits and complete all study requirements. They must agree to comply with all study related procedure, including understanding and adhering to the rehabilitation protocol.
  • Patient has primary or secondary knee osteoarthritis.
  • Patient has sufficient bone quality for total knee arthroplasty.
  • Patient is in stable health.
  • Female patients are not pregnant at times of surgery and do not plan on becoming pregnant during the study.

Note: patient can only enter the project with one knee

Exclusion Criteria
  • Neuromuscular or vascular disease in the affected leg.
  • Patients with osteoporosis based on former diagnosis or preoperative DEXA-scan.
  • Fracture sequelae or previous HTO or previous extensive knee surgery.
  • Patients with need of a stem-elongation.
  • Patients who cannot refrain from taking NSAID post-operatively.
  • Patients with metabolic bone disease.
  • Patients with renal disease.
  • Patients with rheumatoid arthritis.
  • Postmenopausal women in estrogenic hormone substitution
  • Patients with a continuous need of systemic cortisone treatment.
  • Non-Spanish citizenship.
  • Patients who do not comprehend the Spanish language (read and speak).
  • Senile dementia.
  • Alcohol abuse - defined as men drinking more than 21 units a week and women drinking more than 14 units a week.
  • Drug abuse.
  • Major psychiatric disease.
  • Metastatic cancer disease and treatment with radiation therapy or chemotherapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Postoperative functional outcome as measured by the Knee and Osteoarthritis Outcome Score (KOOS) and compare if hybrid NexGen LPS TKA leads to equally successful results as the cemented NexGen LPS TKA.1 year

The current study will be designed as equivalence trial. The amount of allowable difference is the margin that defines the "zone of indifference" within which the interventions are considered equivalent.

The KOOS has a Minimally Clinically Important Difference (MCID) of 8 - 10 points, and the standard deviation in a cohort of TKA patients is ca. 15 points.

The null hypothesis (of non-equivalence) of the study is that functional outcome at 10 years of follow-up in the hybrid group is not equal to the functional outcome at 10 years of follow-up in the cemented group, or:

H: ϑ ≤ ϑ0 - δ1 or ϑ ≥ ϑ0 + δ1, versus the equivalence assumption that functional outcome at 10 years of follow-up in the hybrid group is equivalent to the functional outcome at 10 years of follow-up in the cemented group: K: ϑ0 - δ1 \< ϑ \< ϑ0 + δ1.

Secondary Outcome Measures
NameTimeMethod
Postoperative functional outcome as measured by Knee Society Score.up until 10 years of follow up

The KSS is a questionnaire validate in Spanish.The study regimen for each patient will consist of a screening / baseline phase (Visit 1), follow-up visits (Visits 3 - 9) and a conclusion visit (Visit 10). All procedures specified in this protocol must be documented in the patient's record and on the corresponding Case Report Form (CRF).

Incidence and extend of radiolucent lines (RLL) as measured by standard radiography.Up to 10 years.

Radiography: x-rays will be taken during visit 4 and visits 7-10. Conventional anteroposterior and lateral radiographs will be taken at designated time-points. In order to obtain "true orthogonal" radiographs and to reduce the probability of false-negative findings, the lateral image will be obtained under fluoroscopic control. Postoperative radiographs will assess component position and alignment, the incidence and location of radiolucent lines using the Knee Society TKA radiographic evaluation system.

Trial Locations

Locations (1)

Hospital Galdakao-Usansolo

🇪🇸

Galdakao, Bizkaia, Spain

Hospital Galdakao-Usansolo
🇪🇸Galdakao, Bizkaia, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.